Sangamo Therapeutics (SGMO) Non-Current Deffered Revenue (2016 - 2025)
Historic Non-Current Deffered Revenue for Sangamo Therapeutics (SGMO) over the last 16 years, with Q3 2025 value amounting to $5.9 million.
- Sangamo Therapeutics' Non-Current Deffered Revenue changed N/A to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is N/A changed from last year.
- Per Sangamo Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $5.9 million for Q3 2025.
- Sangamo Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $222.3 million during Q1 2021, with a 5-year trough of $1.8 million in Q1 2023.
- In the last 5 years, Sangamo Therapeutics' Non-Current Deffered Revenue had a median value of $115.6 million in 2022 and averaged $100.4 million.
- As far as peak fluctuations go, Sangamo Therapeutics' Non-Current Deffered Revenue surged by 19529.19% in 2021, and later crashed by 9879.5% in 2023.
- Sangamo Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $166.8 million in 2021, then tumbled by 34.42% to $109.4 million in 2022, then crashed by 98.34% to $1.8 million in 2023, then soared by 223.46% to $5.9 million in 2024, then changed by 0.0% to $5.9 million in 2025.
- Its Non-Current Deffered Revenue stands at $5.9 million for Q3 2025, versus $5.9 million for Q2 2025 and $5.9 million for Q1 2025.